Jacky Visser, John Lawrence, Chris Reed, Jean Wagemans, Douglas Walton
Annotating Argument Schemes
Argumentation
innovation seasonal influenza vaccine development resulted wider range formulations becoming available understanding vaccine coverage across populations including timing administration important evaluating vaccine benefits risks study aims report representativeness uptake influenza vaccines different formulations influenza vaccines timing administration within english primary care sentinel cohort pcsc used pcsc oxfordroyal college general practitioners research surveillance centre included patients ages registered pcsc member general practices reporting influenza vaccine coverage september 1 2019 january 29 2020 identified influenza vaccination recipients characterized age clinical risk groups vaccine type reported date influenza vaccination within pcsc international standard organization iso week representativeness pcsc population compared population data provided office national statistics pcsc influenza vaccine coverage compared published uk health security agencys national data used paired tests compare populations reported 95 ci pcsc comprised 7010627 people 693 general practices study population included greater proportion people aged 1849 years 29823907010627 425 95 ci 425426 compared office national statistics 2019 midyear population estimates 2321973056286961 413 95 ci 412413 p001 people deprived underrepresented least deprived quintile overrepresented within study population 247 17310627010627 95 ci 247247 people ages received influenza vaccine compared 242 1446866559764928 95 ci 242242 p001 national data highest coverage people aged 65 years 9136951264700 723 95 ci 722723 proportion people risk groups received influenza vaccine also higher example 698 284280407228 95 ci 69770 people diabetes pcsc received influenza vaccine compared 612 9837271607996 95 ci 611613 p001 national data pcsc vaccine type brand information available 718 358365498923 95 ci 71772 people aged 1664 years 819 748312913695 95 ci 81882 people aged 65 years compared 236 6968802900000 178 13858887700000 respectively age groups national data vaccination commenced iso week 35 continued iso week 3 peaked iso week 41 inweek peak vaccination administration saturdays pcscs sociodemographic profile similar national population captured data risk groups vaccine brands batches may reflect higher data quality capabilities included reporting precise dates administration pcsc suitable undertaking studies influenza vaccine coverage